FR2663543A1 - HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME. - Google Patents
HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME. Download PDFInfo
- Publication number
- FR2663543A1 FR2663543A1 FR9007837A FR9007837A FR2663543A1 FR 2663543 A1 FR2663543 A1 FR 2663543A1 FR 9007837 A FR9007837 A FR 9007837A FR 9007837 A FR9007837 A FR 9007837A FR 2663543 A1 FR2663543 A1 FR 2663543A1
- Authority
- FR
- France
- Prior art keywords
- lyophilisate
- content
- active principle
- total
- petiron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract 3
- 235000009508 confectionery Nutrition 0.000 title claims description 3
- 235000009854 Cucurbita moschata Nutrition 0.000 claims abstract description 9
- 235000000832 Ayote Nutrition 0.000 claims abstract description 8
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims abstract description 8
- 235000015136 pumpkin Nutrition 0.000 claims abstract description 8
- 240000001980 Cucurbita pepo Species 0.000 claims abstract description 7
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 4
- 150000001747 carotenoids Chemical class 0.000 claims abstract description 4
- 230000001754 anti-pyretic effect Effects 0.000 claims abstract 2
- 239000002221 antipyretic Substances 0.000 claims abstract 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 229910001385 heavy metal Inorganic materials 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims 2
- 230000000146 antalgic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 abstract description 3
- 229960002537 betamethasone Drugs 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003119 painkilling effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N beta-Carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 4
- 241000219122 Cucurbita Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000219109 Citrullus Species 0.000 description 2
- 241000219112 Cucumis Species 0.000 description 2
- 240000008067 Cucumis sativus Species 0.000 description 2
- 235000009852 Cucurbita pepo Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000219106 Bryonia Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 235000010071 Cucumis prophetarum Nutrition 0.000 description 1
- 235000009849 Cucumis sativus Nutrition 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000219136 Lagenaria Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000004487 encapsulated granule Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Les Cucurbitacées constituent une famille de plantes dicotylédones annuelles répandues dans tous les pays du monde dont les fruits comestibles tels que courges, citrouilles, potirons (cucurbita), melons, concombres (cucumis), pastèques (citrullus), calebasses (Lagenaria) sont largement consommés. Cucurbits are a family of annual broadleaf plants widespread in all countries of the world whose edible fruits such as squash, pumpkins, pumpkins (cucurbita), melons, cucumbers (cucumis), watermelons (citrullus), gourds (Lagenaria) are widely consumed .
Depuis la plus haute Antiquité, ces plantes sont connues pour leurs vertus thérapeutiques bénéfiques et certaines variétés non comestibles, la Bryone (Bryonia), le concombre d'âne (Echallium) pour leur toxicité. Since ancient times, these plants have been known for their beneficial therapeutic properties and certain inedible varieties, Bryone (Bryonia), donkey cucumber (Echallium) for their toxicity.
Elles ont donné lieu à de multiples recherches botaniques, pharmacochimiques, pharmacodynamiques et à des applications thérapeutiques diverses ainsi qu'à de très nombreuses publications et demandes de brevets. They have given rise to numerous botanical, pharmacochemical, pharmacodynamic research and various therapeutic applications as well as to numerous publications and patent applications.
Ces recherches se sont heurtées à la complexité chimique de ces plantes et en conséquence à l'instabilité des résultats recueillis, en raison de la variété infinie des différentes espèces étudiées, non seulement, l'une par rapport à l'autre, mais encore dans chaque espèce à la variation des sources, des saisons, des années, des terrains ensemencés, des façons culturales. This research came up against the chemical complexity of these plants and consequently the instability of the results collected, due to the infinite variety of the different species studied, not only in relation to each other, but also in each species with the variation of the sources, the seasons, the years, the sown grounds, the cultural ways.
La présente invention est relative à un nouveau lyophilisat d'extrait total de potiron doux hybride. The present invention relates to a new lyophilisate of total extract of hybrid sweet pumpkin.
Ce lyophilisat est obtenu à partir d'une variété sélectionnée depuis 12 ans par hybridations successives. La plante est élevée sous contrat de culture biologique. Les contrôles sont effectués périodiquement au niveau du terrain et des eaux de ruissellement au cours et en fin de production. Ce potiron cueilli à maturité, lavé, broyé avec écorce, pulpe et pépins est lyophilisé selon un procédé classique, puis rendu bactériologiquement stable par irradiation au rayonnement gamma. This lyophilisate is obtained from a variety selected for 12 years by successive hybridizations. The plant is raised under organic cultivation contract. The controls are carried out periodically at the level of the ground and runoff during and at the end of production. This pumpkin picked at maturity, washed, ground with bark, pulp and seeds is lyophilized according to a conventional process, then made bacteriologically stable by irradiation with gamma radiation.
La stabilité génétique obtenue par une culture étroitement contrôlée sur une longue période, facilite la standardisation des constantes physico-chimiques du lyophilisat ainsi obtenu. The genetic stability obtained by a tightly controlled culture over a long period facilitates the standardization of the physico-chemical constants of the lyophilisate thus obtained.
Celui-ci présente les caractéristiques suivantes
Caractères Triacroscopiques et organoleptiques
Poudre fine, homogène et couleur jaune-orange indélébile.This has the following characteristics
Triacroscopic and organoleptic characters
Fine, homogeneous powder and indelible yellow-orange color.
Odeur herbacée, goût farineux. Herbal odor, farinaceous taste.
Caractères microscopiqlles
L'examen au microscope optique d'une préparation de lyophilisat dans une goutte d'eau distillée selon la Fig. 1 décèle la présence de fibres et l'absence de grains d'amidon allongés.Microscopic characters
Examination under an optical microscope of a lyophilisate preparation in a drop of distilled water according to FIG. 1 detects the presence of fibers and the absence of elongated starch grains.
Caractères hactériologiques
- quantité de germes aérobies mesophiles
inférieure ou égale à 5,0. 102.Heteriological characters
- quantity of aerobic mesophilic germs
less than or equal to 5.0. 102.
- quantité de levures et moisissures inférieure ou
égale à 5,0. 102.- less amount of yeast and mold or
equal to 5.0. 102.
- absence de germes pathogènes, à savoir absence
- d'Escherichia Coli
- de Staphylococcus aureus
- de Pseudomonas aeruginosa
- de Salmonella typhimurium
Caractères physico-chimiques
- pH compris entre 6,44 et 6,47
- métaux lourds < 2ppm
- teneur en glucides comprise entre 63 et 67 %
- teneur en lipides de 6% + 0,5
- teneur en protéines de 10% * 1%
- teneur en carotenoïdes totaux de 25mg * 10% par
gramme de lyophilisat.- absence of pathogenic germs, namely absence
- of Escherichia Coli
- Staphylococcus aureus
- of Pseudomonas aeruginosa
- of Salmonella typhimurium
Physico-chemical characters
- pH between 6.44 and 6.47
- heavy metals <2ppm
- carbohydrate content between 63 and 67%
- lipid content of 6% + 0.5
- protein content of 10% * 1%
- total carotenoid content of 25mg * 10% per
gram of lyophilisate.
Le dosage est réalisé par spectrophotométrie en ultraviolet à l'aide d'un appareil Perkin-Elmer , par comparaison avec un lot témoin de ss carotène, référence Merck 2236 selon les figures 2 et 3. The assay is carried out by ultraviolet spectrophotometry using a Perkin-Elmer device, by comparison with a control batch of ss carotene, reference Merck 2236 according to FIGS. 2 and 3.
Le produit est insoluble dans l'eau, peu soluble dans l'éthanol et le méthanol, modérément soluble dans l'éther et les huiles, soluble dans le chloroforme. The product is insoluble in water, sparingly soluble in ethanol and methanol, sparingly soluble in ether and oils, soluble in chloroform.
La conservation de ces paramètres est liée au stockage du produit à l'abri des phénomènes de photosynthèse ou d'oxydation dus à la chaleur. The conservation of these parameters is linked to the storage of the product away from photosynthesis or oxidation due to heat.
L'étudie phermacocinétique du lyophilisat révèle que la richesse en provitamines A (ss carotène) et en lipides de ce lyophilisat est trois fois plus importante que les teneurs correspondantes du potiron courant ou de la carotte; par sa forte concentration en caroténoïdes, le composé induit la bio-synthèse du Retinol et favorise une régénération cellulaire rapide accélérant le processus de cicatrisation par stimulation de la mitose cellulaire. L'huile de pépins en incorporant plus de lipides et plus d'acides gras insaturés, linoléiques et linoléniques, à celui-ci est elle-même un facteur important du pouvoir de pénétration des préparations topiques à usage dermatologique et cosmétique réalisés avec le composé.La demi-vie du lyophilisat a été déterminée dans la mesure de quatre à cinq heures pour une dose thérapeutique de 100 mg/kilo/jour. The phermokinetic study of the lyophilisate reveals that the richness in provitamins A (ss carotene) and in lipids of this lyophilisate is three times greater than the corresponding contents of the current pumpkin or of the carrot; by its high concentration of carotenoids, the compound induces the bio-synthesis of Retinol and promotes rapid cell regeneration accelerating the healing process by stimulation of cell mitosis. The seed oil by incorporating more lipids and more unsaturated fatty acids, linoleic and linolenic, to it is itself an important factor of the penetrating power of topical preparations for dermatological and cosmetic use made with the compound. The half-life of the lyophilisate has been determined to the extent of four to five hours for a therapeutic dose of 100 mg / kg / day.
t'étude towicologique de ce composé a montré
- une très faible toxicité aiguë, la DL 50 déterminée per os chez la souris et le rat étant supérieure à 5 g par kilo;
- une parfaite tolérance après six mois d'administration répétée chez le rat des deux sexes, objectivée par les examens pondéraux, hématologiques, bio-chimiques et anatomo-pathologiques.the towological study of this compound has shown
- very low acute toxicity, the LD 50 determined per os in mice and rats being greater than 5 g per kilo;
- perfect tolerance after six months of repeated administration in rats of both sexes, demonstrated by weight, hematological, bio-chemical and anatomo-pathological examinations.
L'étude Dharmacoloiaue l'activité anti-inflammatoire a été mise en évidence tant per os que par voie topique selon les méthodes de
- l'oedème à la carragénine
- l'oedème au kaolin.The Dharmacoloiaue study of anti-inflammatory activity was demonstrated both per os and topically according to the methods of
- carrageenan edema
- edema with kaolin.
L'examen des résultats donnés figure 4 montre que le lypohilisat de potiron administré tant en poudre par la voie orale qu'en gel par la voie cutanée possède une activité anti-inflammatoire hautement significative la première heure et importante les deuxième et troisième heures après chaque prise. Examination of the results given in FIG. 4 shows that the pumpkin lypohilisate administered both in powder form by the oral route and in gel by the cutaneous route has a highly significant anti-inflammatory activity the first hour and significant the second and third hours after each taken.
Dans les mêmes conditions expérimentales, l'action de la betamethasone s'est montrée significative à la première heure, non significative à la deuxième heure, nulle à la troisième.Under the same experimental conditions, the action of betamethasone was shown to be significant at the first hour, not significant at the second hour, zero at the third.
L'activité analgésique a été recherchée et objectivée chez le rat selon la technique de La Belle et Tislow. Les résultats consignés dans la figure 5 montrent que le lyophilisat testé comparativement à la betaméthasone possède une activité égale, voire supérieure à celle-ci. The analgesic activity was sought and objectified in rats according to the technique of La Belle and Tislow. The results recorded in FIG. 5 show that the lyophilisate tested compared to betamethasone has an activity equal to, or even greater than, this.
Les exemples d'applications thérapeutiques indiqués ci-après illustrent plus en détail l'invention sans en limiter la portée, le produit pouvant être prescrit et utilisé seul ou en association avec d'autres principes actifs. The examples of therapeutic applications indicated below illustrate the invention in more detail without limiting its scope, the product can be prescribed and used alone or in combination with other active ingredients.
EXEMPT.E 1
Préparation orale sous forme de granulé micro-encapsulé permettant grâce à un support la libération en moins d'une heure d'une demi-dose d'1,5 g de principe actif et cinq heures après d'une deuxième dose d'1,5 g. Administrée selon une posologie de deux prises par jour, une le matin, l'autre le soir, cette forme pharmaceutique absorbée pendant une à deux semaines, réduit totalement les manifestations inflammatoires et douloureuses.EXEMPT.E 1
Oral preparation in the form of a micro-encapsulated granule allowing, thanks to a support, the release in less than an hour of a half-dose of 1.5 g of active principle and five hours after a second dose of 1, 5 g. Administered in a dosage of two times a day, one in the morning, the other in the evening, this pharmaceutical form absorbed for one to two weeks, completely reduces inflammatory and painful manifestations.
EXEMPTE 2
Préparation topique (gel, crème ou pommade) permettant grâce à un excipient, huileux ou non, convenablement choisi une application toutes les 2 ou 3 heures sur les parties lésées un dosage de principe actif compris entre 2 et 10% procure une disparition rapide de l'inflammation et/ou de la douleur.EXAMPLE 2
Topical preparation (gel, cream or ointment) allowing, thanks to an excipient, oily or not, suitably chosen an application every 2 or 3 hours on the injured parts a dosage of active ingredient between 2 and 10% provides a rapid disappearance of the inflammation and / or pain.
EXRMPLE 3
Préparation topique du principe actif suspendu à raison de 50 à 60 mg de lyophilisat dans 100 ml de liquide propulsé par un gaz inerte autorisé tel que l'azote, ce type de forme pharmaceutique étant particulièrement indiqué dans le traitement des brûlures et des escarres. EXRMPLE 3
Topical preparation of the active ingredient suspended in an amount of 50 to 60 mg of lyophilisate in 100 ml of liquid propelled by an authorized inert gas such as nitrogen, this type of pharmaceutical form being particularly indicated in the treatment of burns and bedsores.
Claims (3)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9007837A FR2663543B1 (en) | 1990-06-22 | 1990-06-22 | HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME. |
| EP91912699A EP0489144A1 (en) | 1990-06-22 | 1991-06-18 | Freeze-dried hybrid mild pumpkin and drugs containing same |
| CA002065032A CA2065032A1 (en) | 1990-06-22 | 1991-06-18 | Freeze-dried hybrid mild pumpkin and drugs containing same |
| PCT/FR1991/000486 WO1992000085A1 (en) | 1990-06-22 | 1991-06-18 | Freeze-dried hybrid mild pumpkin and drugs containing same |
| KR1019920700366A KR920702227A (en) | 1990-06-22 | 1991-06-18 | Lyophilized Samples of Hybrid Pumpkin and Drugs Containing the Same |
| JP3511660A JPH05500823A (en) | 1990-06-22 | 1991-06-18 | Freeze-dried hybrid pumpkin with low irritation and medicine containing the same |
| IL98571A IL98571A0 (en) | 1990-06-22 | 1991-06-20 | Lyophilisate of hybrid sweet pumpkin and medicaments containing it |
| ZA914782A ZA914782B (en) | 1990-06-22 | 1991-06-21 | Lyophilisate of hybrid sweet pumpkin and medicaments containing it |
| IE215591A IE912155A1 (en) | 1990-06-22 | 1991-06-21 | Lyophilisate of hybrid sweet pumpkin and medicaments¹containing it |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9007837A FR2663543B1 (en) | 1990-06-22 | 1990-06-22 | HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2663543A1 true FR2663543A1 (en) | 1991-12-27 |
| FR2663543B1 FR2663543B1 (en) | 1992-10-16 |
Family
ID=9397897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9007837A Expired - Lifetime FR2663543B1 (en) | 1990-06-22 | 1990-06-22 | HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0489144A1 (en) |
| JP (1) | JPH05500823A (en) |
| KR (1) | KR920702227A (en) |
| CA (1) | CA2065032A1 (en) |
| FR (1) | FR2663543B1 (en) |
| IE (1) | IE912155A1 (en) |
| IL (1) | IL98571A0 (en) |
| WO (1) | WO1992000085A1 (en) |
| ZA (1) | ZA914782B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2760366A1 (en) * | 1997-03-04 | 1998-09-11 | Harbex Limited | Powdered sweet pumpkin hydrolysate preparation in high yield |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4408330A1 (en) | 1994-03-11 | 1995-09-14 | Cherry Mikroschalter Gmbh | Ergonomic keyboard |
| FR2732347A1 (en) * | 1995-03-30 | 1996-10-04 | Bio Media | Plant extract used as cell growth factor medicament with antitumoural and anticancer activity |
| PT912191E (en) * | 1997-04-16 | 2003-09-30 | Hubert Jean Marie Fr Gillessen | METHOD FOR THE PREPARATION OF THIS AND ITS APPLICATIONS IN HUMAN AND VETERINARY MEDICINE |
| FR2836046B1 (en) * | 2002-02-15 | 2006-09-15 | Marie Jose Touche | NOVEL THERAPEUTIC APPLICATION OF COMPOUND A: BUTOFORM OR SCUROFORM ASSOCIATED WITH PRODUCT B: EUGENOL AND PRODUCT C: ZINC OXIDE, ADDED TO LYCOPENE |
| CN107456562A (en) * | 2017-08-10 | 2017-12-12 | 靖西市民族医药协会 | One kind is brought down a fever wine and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL63333C (en) * | 1900-01-01 | |||
| FR2522500A1 (en) * | 1982-03-02 | 1983-09-09 | Rougereau Andre | Chinese pumpkin or okaido or analogous cucurbitaceae pulp - used as medicament and cosmetic having antiinflammatory, antipyretic, analgesic, antiallergic, keratolytic, skin penetrating etc. activity |
-
1990
- 1990-06-22 FR FR9007837A patent/FR2663543B1/en not_active Expired - Lifetime
-
1991
- 1991-06-18 KR KR1019920700366A patent/KR920702227A/en not_active Withdrawn
- 1991-06-18 JP JP3511660A patent/JPH05500823A/en active Pending
- 1991-06-18 EP EP91912699A patent/EP0489144A1/en not_active Withdrawn
- 1991-06-18 WO PCT/FR1991/000486 patent/WO1992000085A1/en not_active Ceased
- 1991-06-18 CA CA002065032A patent/CA2065032A1/en not_active Abandoned
- 1991-06-20 IL IL98571A patent/IL98571A0/en unknown
- 1991-06-21 IE IE215591A patent/IE912155A1/en unknown
- 1991-06-21 ZA ZA914782A patent/ZA914782B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL63333C (en) * | 1900-01-01 | |||
| FR2522500A1 (en) * | 1982-03-02 | 1983-09-09 | Rougereau Andre | Chinese pumpkin or okaido or analogous cucurbitaceae pulp - used as medicament and cosmetic having antiinflammatory, antipyretic, analgesic, antiallergic, keratolytic, skin penetrating etc. activity |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2760366A1 (en) * | 1997-03-04 | 1998-09-11 | Harbex Limited | Powdered sweet pumpkin hydrolysate preparation in high yield |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0489144A1 (en) | 1992-06-10 |
| JPH05500823A (en) | 1993-02-18 |
| IL98571A0 (en) | 1992-07-15 |
| FR2663543B1 (en) | 1992-10-16 |
| CA2065032A1 (en) | 1991-12-23 |
| ZA914782B (en) | 1992-03-25 |
| IE912155A1 (en) | 1992-01-01 |
| KR920702227A (en) | 1992-09-03 |
| WO1992000085A1 (en) | 1992-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0022046B1 (en) | Drug composition based on plants and process for its preparation | |
| Nwosu | Ethnobotanical studies on some pteridophytes of Southern Nigeria | |
| WO2000041708A1 (en) | Composition for treating obesity and aesthetic treatment method | |
| CH674617A5 (en) | ||
| US8668944B2 (en) | Topical oil for treating physical ailments and method for making and applying the same | |
| EP3454875A1 (en) | Method for producing celastrol and pentacyclic triterpene derivatives | |
| FR2663543A1 (en) | HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME. | |
| US5665360A (en) | Method of treating peripheral neuropathies of the feet and legs | |
| Norten | Neem: India's miraculous healing plant | |
| WO2021099453A1 (en) | Aqueous liquid extract of spirulina for preventing and/or treating peripheral chemotherapy-induced neuropathies and the symptoms thereof, and corresponding composition and use | |
| FR2513122A1 (en) | NEW MEDICINES BASED ON ALGAE EXTRACTS AND CORRESPONDING FORMULATIONS | |
| FR2953725A1 (en) | PROCESS FOR OBTAINING STANDARDIZED EXTRACT OF QUERCETIN AND 3-O-METHYLQUERCETIN FROM MACELA-DO-CAMPO INFLORESCENCE AND COSMETIC, PHARMACEUTICAL AND VETERINARY COMPOSITION CONTAINING THE SAME | |
| CA2725770C (en) | Plant-based compositions and uses | |
| BE1000189A3 (en) | Pharmaceutical preparation for animal treatment. | |
| RU2203081C1 (en) | Islacet preparation for preventing and treating tuberculosis and method for its embodiment | |
| FR2884828A1 (en) | BASIS OF PRODUCTS COMPRISING PLANTS HAVING ST IMULANT PROPERTIES FOR THE NERVOUS SYSTEM AND PSYCHOTROPIC, APHRODISIVE AND DEPURATIVE ENERGETIC ANTIOXIDANT | |
| FR2991181A1 (en) | Composition, useful for inhibiting intestinal absorption of sugar and for treating metabolic syndrome and diabetes, and as a medicament or dietetic product against weight gain, comprises an aqueous extract of Boscia senegalensis | |
| FR2878163A1 (en) | NOVEL PHARMACEUTICAL COMPOSITIONS WITH A PHYTOTHERAPEUTIC VIEW | |
| RU2722067C2 (en) | Herbal medicinal liqueur and method for production thereof | |
| US20070202207A1 (en) | Use of naturally occurring epoxidised molecules from Vernonia Galamensis | |
| FR2686019A1 (en) | Composition of sap and of plant extract | |
| EP0404660B1 (en) | Use of glycoprotein complex extracts of gram (-) bacteria for the preparation of a medicament to facilitate the cicatrisation of the skin and a method for its preparation | |
| FENTOUS et al. | Etude phytochimique et valorisation des extraits bruts des feuilles de grenadier d’Ain Témouchent «Punica granatum» par l'étude de son activité antioxydante | |
| WO2022090561A1 (en) | Natural composition for gastric treatment, particularly for treating gastric ulcers, associated manufacturing method and administration thereof to equids | |
| OA20988A (en) | Phytomedicine based on extracts of two medicinal plants for the treatment of uncomplicated malaria and its preparation process. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property | ||
| ST | Notification of lapse |